martedì, 11 agosto 2026

Notizie AIOM – anno XVII n. 748

3 Dicembre 2019

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial

Immunotherapy in combination with chemotherapy has shown promising efficacy across many different tumour types. We report the prespecified second interim overall survival analysis of the phase 3 IMpassion130 study assessing the efficacy and safety of atezolizumab plus nab-paclitaxel ...
Leggi tutto

3 Dicembre 2019

Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First‐Line Palliative Chemotherapy

Polypharmacy is an important issue in the care of older patients with cancer, as it increases the risk of unfavorable outcomes. We estimated the prevalence of polypharmacy, potentially inappropriate medication (PIM) use, and drug–drug interactions (DDIs) in older patients ...
Leggi tutto

2 Dicembre 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 Novemver 2019

November 29, 2019 - At its monthly meeting, EMA’s safety committee (PRAC) carried out its broad range of responsibilities, which cover all aspects of the risk management of the use of medicines: assessment of safety signals, risk management plans, periodic safety update ...
Leggi tutto

2 Dicembre 2019

Clinical progression is associated with poor prognosis whatever the treatment line in metastatic castration resistant prostate cancer: The CATS international database

Our goal was to evaluate the impact of progression type (prostate-specific antigen only, radiological or clinical) at initiation of first-, second- and third life-extending therapy (LET) on treatment outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients, ...
Leggi tutto

2 Dicembre 2019

ASTRO Presents First Guideline for RT in Pancreatic Cancer

November 30, 2019 - Recent strides in systemic treatment approaches and the broader application of stereotactic radiation led the American Society for Radiation Oncology (ASTRO) to issue its first guideline regarding radiation therapy (RT) in patients with pancreatic cancer, ...
Leggi tutto

29 Novembre 2019

Enzalutamide Gains Approval in China for mCRPC

November 27, 2019 - China’s National Medical Products Administration has granted approval to enzalutamide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic following progression on ...
Leggi tutto

29 Novembre 2019

ASCO Launches New Payment Reform Model to Transform Cancer Care Delivery and Enhance the Quality of Patient Care

November 26, 2019 - The American Society of Clinical Oncology (ASCO) released today a major update to its Patient-Centered Oncology Payment (PCOP) model, an alternative payment model designed to support transformation in cancer care delivery and reimbursement while ensuring ...
Leggi tutto

29 Novembre 2019

FDA Label Change Takes a Bite Out of Prescriptions

November 26, 2019 - Immunotherapy prescriptions for patients with metastatic bladder cancer declined rapidly after the FDA altered the indications of 2 drugs, suggesting that practicing oncologists can keep pace with changes associated with the agency’s accelerated ...
Leggi tutto

29 Novembre 2019

29 novembre 2019 – Attivazione Registro Radio-223 dicloruro (Bayer)

28 Novembre 2019

25 novembre 2019 – Rapporto “L’uso degli antibiotici in Italia” 2018